AZN's Iressa fails NSCLC Phase III

In the confirmatory Phase III ISEL trial, Iressa gefitinib from AstraZeneca (LSE:AZN; AZN) failed to significantly prolong survival in 1,700 non-small cell lung cancer (NSCLC) patients compared with placebo, the primary

Read the full 311 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE